<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794572</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2012-04</org_study_id>
    <secondary_id>2012-001473-91</secondary_id>
    <nct_id>NCT01794572</nct_id>
  </id_info>
  <brief_title>Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse</brief_title>
  <acronym>TOMMY</acronym>
  <official_title>Phase 1-2 Study of the Combination of Escalated Total Bone Marrow Irradiation (TBMI) by Helicoidal Tomotherapy and a Fixed High-dose Melphalan (140 mg/m²) Followed by Peripheral Stem Cell Rescue (PSC) in First Relapsed Multiple Myeloma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Multiple Myeloma, an adult hematological malignancy, mainly located in the Bone Marrow
      (BM), dramatic recent progresses have been observed, thanks to new agents (proteasome
      inhibitors and IMIDs). However, at time of first relapse, high-dose therapy followed by Stem
      Cell Rescue (SCR) is frequently mandatory as a consolidation in minimal residual disease, to
      healthy patients under 65 yo, combining Melphalan (MPH) and/or Total Body Irradiation. Modern
      irradiation modalities are now available by the use of HI-ART Tomotherapy system to realize a
      Total Bone Marrow Irradiation (TBMI), in order both to limit the dose administered to Organ
      at Risk (lungs, oral cavity) and to focus efficacy on BM. In this phase-1 study, the
      conditioning regimen before SCR will combine a fixed high-dose MPH (140 mg/m²) and a dose
      escalated TBMI, so as to define its Maximal Tolerated Dose (MTD) and the Dose Limiting
      Toxicities (DLT). An extended cohort will further in a phase-2 setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental :

      Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2
      fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are
      determined according to a &quot;3x3&quot; modified Fibonacci method and five dose levels will be
      explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently
      the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.

      Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.

      Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day &quot;0&quot; after
      adequate premedication.

      Despite the recent finding of new drugs (proteasome inhibitors and IMIDs), Multiple Myeloma
      still remain uncurable, especially after the first relapse, even in responding disease under
      conventional chemotherapy. In the healthy youngest patients (&lt;65 yo), when peripheral stem
      cells collection is available, a high-dose therapy is often proposed in consolidation of
      complete or very good partial remission: the conditioning regimen usually includes high dose
      alkylating agent (mostly Melphalan) and/or Total Body Irradiation. The new Tomotherapy HI-ART
      technology allows irradiating on a 1.6m length field all the bone marrow sites together with
      optimal respect of the Organ at Risk (lungs, oral cavity, heart, liver, kidneys…). The
      proposed phase-1 study will explore the safety and efficacy of escalated dose of Total
      Bone-Marrow Irradiation in combination with a fixed dose of Melphalan (140mg/m²), followed by
      autologous SCR. To determine the MTD is the main objective of the study, then the toxicity
      profile (DLTs) and the RP2D in an extended cohort at the MTD dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerated Dose, type of DLTs</measure>
    <time_frame>1 year</time_frame>
    <description>Maximal Tolerated Dose Type of Dose-limiting Toxicities The escalated dose levels are determined according to a &quot;3x3&quot; modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile Recommended Dose for Phase-2 (RDP2)</measure>
    <time_frame>1 year</time_frame>
    <description>Safety profile: acute, short and middle term toxicities Recommended Dose for Phase-2 (RDP2) and Extended Cohort for 14 patients at this dose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Bone-marrow control evaluation by FDG PET-Scan Disease-free survival at 1 year and Overall Survival</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <arm_group>
    <arm_group_label>Total BM irradiation dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a &quot;3x3&quot; modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.
For Every patients:
Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.
Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day &quot;0&quot; after adequate premedication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).</description>
    <arm_group_label>Total BM irradiation dose</arm_group_label>
    <other_name>Phenylalanin Mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem cell</intervention_name>
    <description>Autologous Peripheral Stem Cell Rescue : 2.5 10^6 CD-34/Kg are re-infused in the central line on day &quot;0&quot; after adequate premedication.</description>
    <arm_group_label>Total BM irradiation dose</arm_group_label>
    <other_name>Hematopoietic stem cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multiple Myeloma in first relapse.

          -  In Complete or very good partial remission

          -  Available Collected Autologous Peripheral Stem cells: 2.5x106 CD34+/Kg

        Exclusion Criteria:

          -  Uncontrolled visceral disease: kidney, heart, lung, diabetes mellitus

          -  Previous Total body irradiation

          -  Any previous radiation dose to the spinal cord which could reach to 45gy equivalent,
             including the proposed TBMI

          -  Amyloidosis

          -  Brain localizations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc A MAHE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancerologie de l'Ouest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe MOREAU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, CHU de NANTES</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc A MAHE, MD, PhD</last_name>
    <phone>+33 240679900</phone>
    <email>marc-andre.mahe@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francois JL PEIN, MD</last_name>
    <phone>+33 240679908</phone>
    <email>francois.pein@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CLCC Bergonie, service de radiotherapie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benedicte Henriques de Figueiredo, MD</last_name>
      <phone>+33 556333366</phone>
      <email>b.henriques@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Benedicte Henriques de Figueriredo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Haut-Leveque, service d'Hématologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerald Marit, MD, PhD</last_name>
      <phone>+33 556795679</phone>
      <email>gerald.marit@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Gerald Marit, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLCC Oscar Lambret, service de radiothérapie</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lartigau, MD, PhD</last_name>
      <phone>+33 320295911</phone>
      <email>e-lartigau@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Lartigau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Claude Huriez, service d'hématologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Facon, MD, PhD</last_name>
      <phone>+33 320445962</phone>
      <email>thierry.facon@chru.lille.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Facon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLCC ICO, service de radiothérapie</name>
      <address>
        <city>Nantes, St Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc A Mahé, MD, PhD</last_name>
      <phone>+33 240679900</phone>
      <email>marc-andre.mahe@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marc A Mahé, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hotel-Dieu, service d'hématologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Moreau, MD, PhD</last_name>
      <phone>+33 240083260</phone>
      <email>philippe.moreau@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Moreau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLCC Paul Strauss, service de radiothérapie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges Noel, MD, PhD</last_name>
      <phone>+33 88252478</phone>
      <email>gnoel@strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Gerard Noel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre, service d'hématologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Lioure, MD, PhD</last_name>
      <phone>+33 88 127676</phone>
      <email>bruno.lioure@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Lioure, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Wong JY, Rosenthal J, Liu A, Schultheiss T, Forman S, Somlo G. Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):273-9. doi: 10.1016/j.ijrobp.2008.04.071. Epub 2008 Sep 9.</citation>
    <PMID>18786784</PMID>
  </reference>
  <reference>
    <citation>Somlo G, Spielberger R, Frankel P, Karanes C, Krishnan A, Parker P, Popplewell L, Sahebi F, Kogut N, Snyder D, Liu A, Schultheiss T, Forman S, Wong JY. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res. 2011 Jan 1;17(1):174-82. doi: 10.1158/1078-0432.CCR-10-1912. Epub 2010 Nov 3.</citation>
    <PMID>21047977</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapse</keyword>
  <keyword>Complete Remission</keyword>
  <keyword>Very Good Partial Remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

